secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001420720-26-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio reports Q2 FY2026 operating loss; secures $26M PIPE financing led by Frazier Life Sciences
--------------------------------------------------------------------------------

- No revenue for Q2 ended Dec 31, 2025, vs $0.2M a year ago; R&D expense $4.3M, G&A $5.2M (includes impairment of IBIO-101 intangible).
- Cash and investments of $52.7M at Dec 31, 2025; net proceeds of ~$24.4M from January PIPE extend runway into Q3 FY2028.
- IBIO-600 (myostatin antibody) on track for Phase 1a clinical trial in H1 2026; IBIO-610 (activin E) aims for first human trials early 2027.
- NHP data for IBIO-610 shows predicted human half-life up to 100 days, supporting twice-yearly dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000003/0001420720-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000003/ibio-20260210x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer